Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
Intra-articular Dexmedetomidine for Treatment of Chronic Knee Pain: A Prospective Case-Control Clinical Trial
Tanta University
70 participants
Sep 17, 2024
INTERVENTIONAL
Conditions
Summary
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.
Eligibility
Inclusion Criteria1
- Patients were not assigned for surgical intervention;
Exclusion Criteria5
- Patients were assigned for surgical intervention;
- Patients who had uncontrolled hypertension and/or diabetes mellitus;
- Patients who had uncompensated cardiac, renal, or hepatic diseases;
- Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs;
- Patients who refused to sign the informed consent were excluded from the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06641206